Related references
Note: Only part of the references are listed.Rituximab in severe, treatment-refractory interstitial lung disease
Gregory J. Keir et al.
RESPIROLOGY (2014)
Immunosuppression for Connective Tissue Disease-Related Pulmonary Disease
Toby M. Maher
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy
Gregory J. Keir et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
Anthony J. Tyndall et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis
C. J. Zappala et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic
F. Perosa et al.
JOURNAL OF INTERNAL MEDICINE (2010)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
Rachel B. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Dimitrios Daoussis et al.
RHEUMATOLOGY (2010)
Is There a Role for B-cell Depletion as Therapy for Scleroderma? A Case Report and Review of the Literature
Dimitrios Daoussis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
Silvia Bosello et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Rituximab treatment of the anti-synthetase syndrome-a retrospective case series
Marthe Sem et al.
RHEUMATOLOGY (2009)
Interstitial lung disease in systemic sclerosis - A simple staging system
Nicole S. L. Goh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
Donald M. Arnold et al.
ANNALS OF INTERNAL MEDICINE (2007)
B cell infiltration in systemic sclerosis-associated interstitial lung disease
Robert Lafyatis et al.
ARTHRITIS AND RHEUMATISM (2007)
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
Rachel K. Hoyles et al.
ARTHRITIS AND RHEUMATISM (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Cyclophosphamide versus placebo in scleroderma lung disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
P Emery et al.
ARTHRITIS AND RHEUMATISM (2006)
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis
MJ Leandro et al.
ARTHRITIS AND RHEUMATISM (2006)
B lymphocyte depletion therapy with rituximab in rheumatoid arthritis
JCW Edwards et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2004)
Gene expression in bronchoalveolar lavage cells from scleroderma patients
IG Luzina et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2002)
Share Paper
